- April 4 - 5, 2022
- Mon, Apr 4
- Tue, Apr 5
Attend the workshop
The U.S. Food and Drug Administration (FDA) and Duke-Margolis are collaborating to host a two-day virtual public workshop focused on identifying gaps in the content of existing opioid prescriber education offerings and core competencies that should be included in educational content for opioid prescribers and other healthcare providers, including prescriber education under a Risk Evaluation and Mitigation Strategy (REMS).
This workshop will build on discussions from the October 2021 Margolis-FDA convening on REMS opioid prescriber education and will include federal agencies, provider associations, licensing and accrediting organizations, education experts, and other key stakeholders aiming to alleviate the opioid and substance use crisis through improved education for opioid prescribers and other healthcare providers.
Key topics explored through workshop discussions will include: 1) Examining Core Competencies for Opioid Prescriber Education, 2) Professional Practice Gaps in Substance Use Disorder and Pain Management and Related Gaps in Current Prescriber Education, 3) Identifying Lessons Learned from Provider Education and Continuing Medical Education Initiatives, and 4) Future Directions and Next Steps for Shaping Future Prescriber Education Efforts.
Funding for this workshop was made possible in part by a cooperative agreement from the U.S. Food and Drug Administration Center for Drug Evaluation and Research. The views expressed in written workshop materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsements by the U.S. Government.